Oncolytics Biotech® to Showcase New Pancreatic Cancer Data at ASCO Highlighting Pelareorep's Tumor-Fighting Mechanism of Action
Oncolytics Biotech (NASDAQ: ONCY) announced it will present new data from Cohort 1 of the GOBLET study at the 2025 ASCO Annual Meeting in Chicago. The presentation will showcase pelareorep's anti-tumor activity in pancreatic ductal adenocarcinoma (PDAC), the most common form of pancreatic cancer.
The data will demonstrate how pelareorep activates immune responses in pancreatic cancer patients. According to Chief Medical Officer Dr. Thomas Heineman, pelareorep has shown encouraging results in multiple studies by engaging the immune system to attack pancreatic cancer tumors, potentially improving outcomes for patients with this hard-to-treat cancer.
The presentation (Abstract #2562) titled 'Role of pelareorep in activating anti-tumor immunity in PDAC' will be delivered as a poster in the Developmental Therapeutics – Immunotherapy session on June 2, 2025.
Oncolytics Biotech (NASDAQ: ONCY) ha annunciato che presenterà nuovi dati della Coorte 1 dello studio GOBLET al 2025 ASCO Annual Meeting di Chicago. La presentazione mostrerà l’attività antitumorale di pelareorep nell’adenocarcinoma duttale pancreatico (PDAC), la forma più comune di cancro al pancreas.
I dati dimostreranno come pelareorep attivi le risposte immunitarie nei pazienti con cancro al pancreas. Secondo il Chief Medical Officer, Dr. Thomas Heineman, pelareorep ha mostrato risultati promettenti in diversi studi stimolando il sistema immunitario ad attaccare i tumori pancreatici, potenzialmente migliorando le prospettive per i pazienti affetti da questo tumore difficile da trattare.
La presentazione (Abstract #2562), intitolata 'Ruolo di pelareorep nell’attivazione dell’immunità antitumorale nel PDAC', sarà esposta come poster nella sessione Developmental Therapeutics – Immunotherapy il 2 giugno 2025.
Oncolytics Biotech (NASDAQ: ONCY) anunció que presentará nuevos datos de la Cohorte 1 del estudio GOBLET en la Reunión Anual ASCO 2025 en Chicago. La presentación mostrará la actividad antitumoral de pelareorep en el adenocarcinoma ductal pancreático (PDAC), la forma más común de cáncer de páncreas.
Los datos demostrarán cómo pelareorep activa las respuestas inmunitarias en pacientes con cáncer de páncreas. Según el Director Médico, Dr. Thomas Heineman, pelareorep ha mostrado resultados alentadores en múltiples estudios al involucrar al sistema inmunológico para atacar los tumores pancreáticos, lo que podría mejorar los resultados para pacientes con este cáncer difícil de tratar.
La presentación (Resumen #2562) titulada 'Rol de pelareorep en la activación de la inmunidad antitumoral en PDAC' se realizará en formato póster durante la sesión de Therapeutics en Desarrollo – Inmunoterapia el 2 de junio de 2025.
Oncolytics Biotech(NASDAQ: ONCY)는 시카고에서 열리는 2025 ASCO 연례회의에서 GOBLET 연구 1코호트의 새로운 데이터를 발표할 예정입니다. 이번 발표에서는 췌관 선암(PDAC)에서 펠라레오렙의 항종양 활성을 소개할 것입니다. PDAC는 췌장암 중 가장 흔한 형태입니다.
데이터는 펠라레오렙이 췌장암 환자의 면역 반응을 어떻게 활성화하는지 보여줍니다. 최고 의료 책임자인 토마스 하이네만 박사에 따르면, 펠라레오렙은 여러 연구에서 면역 체계를 활성화해 췌장암 종양을 공격함으로써 치료가 어려운 이 암 환자의 치료 결과를 개선할 가능성을 보여주었습니다.
'PDAC에서 펠라레오렙의 항종양 면역 활성화 역할'이라는 제목의 발표(Abstract #2562)은 2025년 6월 2일 Developmental Therapeutics – Immunotherapy 세션에서 포스터 형식으로 진행됩니다.
Oncolytics Biotech (NASDAQ : ONCY) a annoncé qu'elle présentera de nouvelles données de la cohorte 1 de l'étude GOBLET lors du Congrès Annuel ASCO 2025 à Chicago. La présentation mettra en lumière l'activité anti-tumorale de pelareorep dans l'adénocarcinome canalaire pancréatique (PDAC), la forme la plus courante de cancer du pancréas.
Les données démontreront comment pelareorep active les réponses immunitaires chez les patients atteints de cancer du pancréas. Selon le directeur médical, le Dr Thomas Heineman, pelareorep a montré des résultats encourageants dans plusieurs études en mobilisant le système immunitaire pour attaquer les tumeurs pancréatiques, ce qui pourrait améliorer le pronostic des patients atteints de ce cancer difficile à traiter.
La présentation (Résumé #2562), intitulée « Rôle de pelareorep dans l’activation de l’immunité anti-tumorale dans le PDAC », sera présentée sous forme de poster lors de la session Developmental Therapeutics – Immunotherapy le 2 juin 2025.
Oncolytics Biotech (NASDAQ: ONCY) gab bekannt, dass neue Daten aus Kohorte 1 der GOBLET-Studie auf dem 2025 ASCO Annual Meeting in Chicago vorgestellt werden. Die Präsentation wird die antitumorale Wirkung von Pelareorep beim duktalen Pankreasadenokarzinom (PDAC), der häufigsten Form von Bauchspeicheldrüsenkrebs, zeigen.
Die Daten werden aufzeigen, wie Pelareorep die Immunantworten bei Patienten mit Bauchspeicheldrüsenkrebs aktiviert. Laut dem Chief Medical Officer Dr. Thomas Heineman hat Pelareorep in mehreren Studien vielversprechende Ergebnisse erzielt, indem es das Immunsystem dazu anregt, Pankreastumore anzugreifen, was die Behandlungsergebnisse für Patienten mit dieser schwer behandelbaren Krebserkrankung verbessern könnte.
Die Präsentation (Abstract #2562) mit dem Titel ‚Rolle von Pelareorep bei der Aktivierung der antitumoralen Immunität bei PDAC‘ wird am 2. Juni 2025 als Poster in der Sitzung Developmental Therapeutics – Immunotherapy vorgestellt.
- Pelareorep demonstrates encouraging results in multiple studies for pancreatic cancer treatment
- Company advancing treatment solution for PDAC, which has treatment options currently
- None.
ASCO data expected to highlight how pelareorep activates immune responses in pancreatic cancer patients
Ongoing updates support potential of pelareorep combination therapies in one of the deadliest and hardest-to-treat cancers
"Pelareorep continues to deliver encouraging results in pancreatic cancer, where few effective treatments exist," said Thomas Heineman, M.D., Ph.D., Chief Medical Officer for Oncolytics Biotech. "In multiple studies, pelareorep has repeatedly demonstrated its ability to engage the immune system to attack pancreatic cancer tumors, which has the potential to improve outcomes for patients battling this difficult-to-treat cancer."
Abstract Number: 2562
Title: Role of pelareorep in activating anti-tumor immunity in PDAC.
Presentation Type: Poster
Session Title: Developmental Therapeutics – Immunotherapy
Session Date and Time: June 2, 2025, 1:30 - 4:30 p.m. CT
Abstracts will be published on the ASCO website at 5:00 p.m. ET on May 22, 2025.
About GOBLET
The GOBLET (Gastrointestinal tumOrs exploring the treatment comBinations with the oncolytic reovirus peLarEorep and anTi-PD-L1) study is a phase 1/2 multiple indication study in advanced or metastatic gastrointestinal tumors. The study is being conducted at 17 centers in
- Pelareorep in combination with atezolizumab, gemcitabine, and nab-paclitaxel in 1st line advanced/metastatic pancreatic cancer patients;
- Pelareorep in combination with atezolizumab in 1st line MSI (microsatellite instability)-high metastatic colorectal cancer patients;
- Pelareorep in combination with atezolizumab and TAS-102 in 3rd line metastatic colorectal cancer patients
- Pelareorep in combination with atezolizumab in 2nd line advanced and unresectable anal cancer patients; and
- Pelareorep in combination with modified FOLFIRINOX with and without atezolizumab in newly diagnosed metastatic PDAC patients.
Any cohort meeting pre-specified efficacy criteria in Stage 1 may be advanced to Stage 2 and enroll additional patients.
About AIO
AIO-Studien-gGmbH (AIO) emerged from the study center of the medical oncology working group within the German Cancer Society (DKG). AIO operates with a non-profit purpose of promoting science and research with a focus on medical oncology. Since its foundation, AIO has become a successful sponsor and study management company and has established itself both nationally and internationally.
About Oncolytics Biotech Inc.
Oncolytics is a clinical-stage biotechnology company developing pelareorep, an intravenously delivered immunotherapeutic agent. Pelareorep has demonstrated promising results in two randomized Phase 2 studies in metastatic breast cancer and Phase 1 and 2 studies in pancreatic cancer. It acts by inducing anti-cancer immune responses and promotes an inflamed tumor phenotype -- turning "cold" tumors "hot" -- through innate and adaptive immune responses to treat a variety of cancers.
Pelareorep has demonstrated synergies with multiple approved oncology treatments. Oncolytics is currently conducting and planning combination clinical trials with pelareorep in solid malignancies as it advances towards registrational studies in metastatic breast cancer and pancreatic cancer, both of which have received Fast Track designation from the FDA. For further information, please visit: www.oncolyticsbiotech.com or follow the company on social media on LinkedIn and on X @oncolytics.
Tecentriq® (atezolizumab) is a registered trademark of Genentech, a member of the Roche Group.
This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended and forward-looking information under applicable Canadian securities laws (such forward-looking statements and forward-looking information are collectively referred to herein as "forward-looking statements"). Forward-looking statements contained in this press release include statements regarding Oncolytics' belief as to the potential, mechanism of action and benefits of pelareorep as a cancer therapeutic; our belief that there are multiple clinical and regulatory options for bringing pelareorep to patients; and other statements related to anticipated developments in Oncolytics' business and technologies. In any forward-looking statement in which Oncolytics expresses an expectation or belief as to future results, such expectations or beliefs are expressed in good faith and are believed to have a reasonable basis, but there can be no assurance that the statement or expectation or belief will be achieved. Such forward-looking statements involve known and unknown risks and uncertainties, which could cause Oncolytics' actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and development projects, the efficacy of pelareorep as a cancer treatment, the success and timely completion of clinical studies and trials, Oncolytics' ability to successfully commercialize pelareorep, uncertainties related to the research and development of pharmaceuticals, uncertainties related to the regulatory process and general changes to the economic environment. We may incur expenses or delays relating to events outside of our control, which could have a material adverse impact on our business, operating results and financial condition. Investors should consult Oncolytics' quarterly and annual filings with the Canadian and
Company Contact
Jon Patton
Director of IR & Communication
jpatton@oncolytics.ca
Investor Relations for Oncolytics
Mike Moyer
LifeSci Advisors
+1-617-308-4306
mmoyer@lifesciadvisors.com
Media Contact for Oncolytics
Michael Rubenstein
LifeSci Communications
mrubenstein@lifescicomms.com
Logo - https://mma.prnewswire.com/media/2408622/5284957/Oncolytics_Biotech_Inc_Logo.jpg
View original content to download multimedia:https://www.prnewswire.com/news-releases/oncolytics-biotech-to-showcase-new-pancreatic-cancer-data-at-asco-highlighting-pelareoreps-tumor-fighting-mechanism-of-action-302437172.html
SOURCE Oncolytics Biotech® Inc.
FAQ
What new data will Oncolytics Biotech (ONCY) present at ASCO 2025?
When and where will ONCY present its pancreatic cancer research findings?
What is the significance of pelareorep in treating pancreatic cancer?
What type of presentation will ONCY deliver at ASCO 2025?
